Think your device won’t get payer traction because it’s outside the “big three”? This article breaks down how MedTech companies targeting niche patient populations can still win with U.S. payers by aligning with quality metrics, cost savings, and equity priorities.
Learn how NTAP, TPT, and NT-APC help MedTech startups bridge the gap between FDA clearance and permanent reimbursement. Early payment can drive adoption.